RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC Cancer Network The mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when given as first-line treatment in patients with metastatic renal cell carcinoma (RCC ... |
